Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | HMBD004 |
Synonyms | |
Therapy Description |
HMBD004 s a bispecific antibody to CD47 and CD33 that blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells and may also stimulate cytotoxic T-cells (PMID: 29873856). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HMBD004 | CD33 Antibody 12 CD47 Antibody 30 Immune Checkpoint Inhibitor 147 | HMBD004 s a bispecific antibody to CD47 and CD33 that blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, leading to phagocytosis of tumor cells and may also stimulate cytotoxic T-cells (PMID: 29873856). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|